Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors

NCT01122199 is registered in ClinicalTrials.gov with Shadia Jalal as lead sponsor.

NCT NCT01122199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01122199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors
Lead sponsor
Shadia Jalal
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2010
Completion date
January 19, 2015
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastases